Cogent Biosciences (COGT) Non Operating Income (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Non Operating Income data on file, last reported at $6.3 million in Q1 2026.

• On a quarterly basis, Non Operating Income rose 112.25% year-over-year to $6.3 million in Q1 2026; TTM through Mar 2026 was $7.7 million, a 59.23% decrease from a year earlier, with the FY2025 full-year figure at $4.4 million, down 77.96% from the prior year.
• Non Operating Income for Q1 2026 stood at $6.3 million, up from -$3.0 million in the prior quarter.
• Over the last five years, Non Operating Income for COGT reached as high as $6.3 million in Q1 2026 and fell as low as -$3.0 million in Q4 2025.
• Historically, Non Operating Income has averaged $3.2 million across 5 years, with a median of $3.9 million in 2023.
• Across the five-year window, Non Operating Income soared 493.11% in 2023 and slumped 151.64% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $4.1 million in 2022, then fell by 6.4% to $3.9 million in 2023, then soared by 50.32% to $5.8 million in 2024, then slumped by 151.64% to -$3.0 million in 2025, then surged by 308.57% to $6.3 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $6.3 million in Q1 2026, -$3.0 million in Q4 2025, and $2.4 million in Q3 2025.